Intellia Therapeutics Stock Forecast, Price & News

Intellia Therapeutics' stock was trading at $12.72 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NTLA shares have increased by 209.6% and is now trading at $39.38.
View which stocks have been most impacted by COVID-19.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Intellia Therapeutics or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Intellia Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Intellia Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Intellia Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Intellia Therapeutics.

Intellia Therapeutics Inc (NASDAQ:NTLA) posted its earnings results on Thursday, November, 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.54) by $0.07. The firm had revenue of $22.22 million for the quarter, compared to analyst estimates of $14.95 million. Intellia Therapeutics had a negative return on equity of 40.57% and a negative net margin of 228.87%. The business's quarterly revenue was up 109.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.49) earnings per share.
View Intellia Therapeutics' earnings history.

11 Wall Street analysts have issued 12-month price objectives for Intellia Therapeutics' stock. Their forecasts range from $20.00 to $57.50. On average, they anticipate Intellia Therapeutics' share price to reach $31.36 in the next twelve months. This suggests that the stock has a possible downside of 20.4%.
View analysts' price targets for Intellia Therapeutics.

Some companies that are related to Intellia Therapeutics include Ipsen (IPSEY), Quidel (QDEL), Neogen (NEOG), Myriad Genetics (MYGN), Heska (HSKA), Lantheus (LNTH), Celldex Therapeutics (CLDX), Meridian Bioscience (VIVO), Quotient (QTNT), Aspira Women's Health (AWH), Oxford Immunotec Global (OXFD), Riot Blockchain (RIOT), VolitionRx (VNRX), VolitionRx (VNRX) and Nymox Pharmaceutical (NYMX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Square (SQ), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC), Invitae (NVTA) and Cisco Systems (CSCO).

(NTLA) raised $85 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

Intellia Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (19.42%), Nikko Asset Management Americas Inc. (10.32%), BlackRock Inc. (9.61%), State Street Corp (5.21%), Morgan Stanley (2.01%) and Point72 Asset Management L.P. (1.11%). Company insiders that own Intellia Therapeutics stock include Andrew Schiermeier, John M Leonard and Jose E Rivera.
View institutional ownership trends for Intellia Therapeutics.

NTLA stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Nikko Asset Management Americas Inc., Jane Street Group LLC, Raymond James Financial Services Advisors Inc., Wells Fargo & Company MN, Platinum Investment Management Ltd., Cubist Systematic Strategies LLC, and Raymond James & Associates. Company insiders that have sold Intellia Therapeutics company stock in the last year include John M Leonard, and Jose E Rivera.
View insider buying and selling activity for Intellia Therapeutics.

NTLA stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, BlackRock Inc., Morgan Stanley, JPMorgan Chase & Co., Engineers Gate Manager LP, AlphaCrest Capital Management LLC, Federated Hermes Inc., and Charles Schwab Investment Management Inc..
View insider buying and selling activity for Intellia Therapeutics.

Shares of NTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NTLA stock can currently be purchased for approximately $39.38.

Intellia Therapeutics has a market capitalization of $2.33 billion and generates $43.10 million in revenue each year. The company earns $-99,530,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Intellia Therapeutics employs 270 workers across the globe.

The official website for Intellia Therapeutics is www.intelliatx.com.

Intellia Therapeutics' mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The company can be reached via phone at 857-285-6200 or via email at [email protected]